Indications: The EVOQUE tricuspid valve replacement system is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation despite being treated …

Feb 26, 2024 · The Edwards EVOQUE Tricuspid Valve Replacement System is an artificial heart valve that can be implanted using a delivery catheter without open-heart surgery.

The Edwards EVOQUE tricuspid valve replacement system (herein referred to as the EVOQUE system) is designed to replace the native tricuspid valve in patients with tricuspid valve …

The Edwards EVOQUE Tricuspid Valve Replacement System (EVOQUE system) is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation …

The TRISCEND II trial is a prospective multi-center randomized controlled trial evaluating the safety and effectiveness of transcatheter tricuspid valve replacement with the EVOQUE …

Feb 2, 2024 · The EVOQUE system is comprised of a nitinol self-expanding frame, intra-annular sealing skirt and tissue leaflets made from the company’s proven bovine pericardial tissue. …

Dec 18, 2024 · Edwards EVOQUE Tricuspid Valve Replacement System. Open in new tab / English | 0 | FAQ Order Paper Copy. Request printed copy Was this helpful? Yes No. Effective …

The Edwards EVOQUE tricuspid valve replacement system (herein referred to as the EVOQUE system) is designed to replace the native tricuspid valve in patients with symptomatic, severe …

Feb 15, 2024 · The U.S. Food and Drug Administration (“FDA”) recently approved the Edwards EVOQUE ® Tricuspid Valve Replacement System (the “EVOQUE ® system”) for use in …

Oct 19, 2023 · Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter …